Shark Tank Judge Namita Thapar Gains Rs 619.25 Crore in a Day as This Pharma Stock Jump Over 8% on Monday
आमच्यासोबत जोडा
आम्हाला फॉलो करा
The stock price has surged over 53.21 per cent in the last 1 year and delivered approximately 68.41 per cent returns from its 52-week low of Rs 889 per share.
✨ AI Powered Summary
On Monday, shares of Emcure Pharmaceuticals Ltd jumped 8.67 per cent to Rs 1,538 per share from its previous closing of Rs 1,415.80 per share. The stock’s 52‑week high is Rs 1,585.60 per share and its 52‑week low is Rs 889 per share.
Shares of Emcure Pharmaceuticals Ltd surged sharply on Monday, March 9, 2026, with the stock reaching an intraday high of Rs 1,538 per share - marking the company’s biggest intraday gain in the last four months, with the previous high recorded on October 6, 2025. The stock witnessed robust trading activity with a volume of 5.20 lakh shares during the session.
Namita Thapar, Executive Director of Emcure Pharmaceuticals, holds a 2.68 per cent stake in the company, amounting to 5,071,200 shares. Based on Monday’s intraday high of Rs 1,538, her holdings appreciated significantly. The gain per share was Rs 122.20 (Rs 1,538 − Rs 1,415.80), resulting in a total gain of approximately Rs 619.25 crore for her stake, a substantial one‑day increase in value.
Foreign institutional investors (FIIs) have also shown growing confidence in Emcure Pharma. In the quarter ending December 2025, FII holdings rose to 3.59 per cent from 3.29 per cent in the previous quarter, reflecting increased investor interest.
Incorporated in 1981, Emcure Pharmaceuticals Ltd develops, manufactures and markets a wide range of pharmaceutical and biopharmaceutical products globally. Its portfolio spans oral solids, oral liquids, injectables — including liposomal and lyophilised injectables — biotherapeutics, and complex APIs such as chiral molecules, iron molecules and cytotoxic products. The company operates across key therapeutic areas including gynaecology, cardiology, blood-related disorders, oncology, respiratory conditions, central nervous system diseases and HIV, with over 350 brands and a presence in more than 70 countries.
The stock’s strong performance saw it surge to its intraday high, reflecting robust market momentum. The company has a market cap of over Rs 28,000 crore. The stock price has surged over 8.67 per cent in the last session. From a 52‑week low of Rs 889 per share, the stock has delivered significant returns.
Disclaimer: The article is for informational purposes only and not investment advice.